GlassScriptPhysician profile
Lee Marie D Harkey
NPI 1225464126
$6,552.23
in general payments reported to CMS, 2019-2025
32 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,581 · 2022: $1,305 · 2023: $1,268 · 2024: $1,167 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,666.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,364.70 | 2021-2025 | Relistor |
| Abbvie INC. | $932.36 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $751.74 | 2021-2025 | Xtampza, Belbuca |
| Forte Bio-Pharma LLC | $340.27 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Pfizer INC. | $337.02 | 2021-2025 | |
| Indivior INC. | $290.16 | 2022-2025 | Sublocade |
| Scilex Pharmaceuticals INC. | $285.45 | 2021-2025 | Ztlido |
| Virtus Pharmaceuticals LLC | $190.27 | 2024-2025 | Levorphanol Tartrate |
| Novo Nordisk INC | $180.29 | 2022-2025 | Wegovy, Saxenda |
| Almatica Pharma LLC | $167.31 | 2021-2023 | Gralise |
| Lundbeck LLC | $164.87 | 2024-2025 | Vyepti |
| Biodelivery Sciences International, INC. | $156.72 | 2021 | |
| Currax Pharmaceuticals LLC | $132.75 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.67 | 2021 | |
| Redhill Biopharma INC. | $116.85 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $109.66 | 2022-2025 | Zepbound |
| Uswm, LLC | $89.53 | 2021-2023 | Zimhi, Lucemyra |
| Hikma Pharmaceuticals USA | $82.92 | 2022 | |
| Orexo US, INC. | $82.83 | 2021-2024 | Zubsolv |
| Amgen INC. | $74.17 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $67.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.83 | 2022 | |
| Valinor Pharma, LLC | $58.74 | 2025 | Movantik |
| Nevro Corp. | $58.62 | 2021-2023 | Senza |
| Boston Scientific Corporation | $58.46 | 2022-2025 | General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $54.77 | 2021-2024 | Ajovy |
| Tonix Medicines, INC. | $50.79 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $50.17 | 2024-2025 | |
| Grt US Holding, INC. | $40.61 | 2021 | |
| Braeburn INC. | $24.82 | 2024 | Brixadi |
| Azurity Pharmaceuticals, INC. | $21.16 | 2023 | Horizant |
| Medtronic, INC. | $21.02 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Marie Harkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.